Fig. 1From: Active targeting of HER2-positive breast cancer cells by Herceptin-functionalized organically modified silica nanoparticlesThe schematic view of the bioconjugation of Nile Red-encapsulated ORMOSIL nanoparticles with HerceptinBack to article page